Ind-Swift
MergedClose ·
No trades in 1Y · Last traded
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Ind-Swift (this company) | ₹15.76 | — | — | — | — | — | 11.90% | ₹501 Cr | — |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,446 Cr | 4.77 | 0.58% | 16.50% | 16.65% | ₹22,862 Cr | ₹3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Key Insights
Strengths
1- Company has delivered good profit growth of 18.2% CAGR over last 5 years
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.35% over past five years.
- Contingent liabilities of Rs.72.4 Cr.
- Earnings include an other income of Rs.328 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 5 | 3 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 43.46
- Neutral
- MACD (12,26,9)
- −0.46
- Bearish
- SMA (50)
- 16.88
- Bearish
- SMA (200)
- 18.41
- Bearish
As of , the latest day with price data, so these readings are not current.
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2025; 1Y: fiscal year to Mar 2025 against Mar 2024.
Revenue
| 10Y | +2.13% |
|---|---|
| 5Y | +9.31% |
| 3Y | +8.97% |
| 1Y | +2.59% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | Turned to profit |
| 3Y | Turned to profit |
| 1Y | Tiny base |
Operating cash flow
| 10Y | −15.48% |
|---|---|
| 5Y | −14.49% |
| 3Y | −31.60% |
| 1Y | +6.67% |
Operating margin· change in pp
| 10Y | +21.26 pp |
|---|---|
| 5Y | −2.50 pp |
| 3Y | −6.84 pp |
| 1Y | −6.29 pp |
Trailing twelve months: The latest quarterly results are more than a year old.
Revenue by year
| Mar 2016 | ₹308 Cr |
|---|---|
| Mar 2017 | ₹263 Cr |
| Mar 2018 | ₹270 Cr |
| Mar 2019 | ₹289 Cr |
| Mar 2020 | ₹330 Cr |
| Mar 2021 | ₹356 Cr |
| Mar 2022 | ₹398 Cr |
| Mar 2023 | ₹411 Cr |
| Mar 2024 | ₹502 Cr |
| Mar 2025 | ₹515 Cr |
Net profit by year
| Mar 2016 | −₹200 Cr |
|---|---|
| Mar 2017 | −₹364 Cr |
| Mar 2018 | −₹54.00 Cr |
| Mar 2019 | ₹8.00 Cr |
| Mar 2020 | −₹19.00 Cr |
| Mar 2021 | −₹30.00 Cr |
| Mar 2022 | −₹20.00 Cr |
| Mar 2023 | ₹26.00 Cr |
| Mar 2024 | ₹14.00 Cr |
| Mar 2025 | ₹283 Cr |
Quarterly Results
₹ CrResults for the period ended Jun 2025 were due by 14 Aug 2025 and are not in this table yet.
| Particulars | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 106 | 95 | 104 | 107 | 106 | 149 | 116 | 103 | 135 | 114 | 136 | 120 | 145 |
| Expenses | 96 | 90 | 93 | 89 | 98 | 130 | 105 | 98 | 121 | 111 | 122 | 112 | 148 |
| Operating Profit | 10 | 5 | 11 | 18 | 8 | 18 | 11 | 4 | 15 | 3 | 14 | 8 | −3 |
| OPM % | 9% | 5% | 11% | 17% | 8% | 12% | 10% | 4.4% | 11% | 2.8% | 11% | 7% | −2% |
| Other Income | 7 | 2 | 1 | 3 | 67 | 6 | 3 | 3 | 46.59 | 40 | 5 | 2.65 | 281 |
| Interest | 14 | 15 | 15 | 15 | 14 | 15 | 18 | 15 | 14 | 10 | 10 | 10 | 10 |
| Depreciation | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 6 | 7 |
| PBT | −5 | −15 | −11 | −1 | 53 | 2 | −11 | −15 | 40 | 28 | 4 | −6 | 261 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 0% | 0% | 0% | 2% |
| Net Profit | −5 | −15 | −11 | −1 | 53 | 2 | −11 | −15 | 38 | 28 | 4 | −6 | 257 |
| EPS (₹) | −1.01 | −2.85 | −1.95 | −0.19 | 9.8 | 0.44 | −1.98 | −2.76 | 6.93 | 5.21 | 0.76 | −1.01 | 47.34 |
Profit & Loss
₹ Cr| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 570 | 417 | 308 | 263 | 270 | 289 | 330 | 356 | 398 | 411 | 502 | 515 |
| Expenses | 602 | 487 | 465 | 328 | 262 | 278 | 306 | 315 | 352 | 369 | 448 | 492 |
| Operating Profit | −32 | −70 | −157 | −65 | 8 | 11 | 23 | 41 | 45 | 42 | 54 | 23 |
| OPM % | −6% | −17% | −51% | −25% | 2.9% | 3.7% | 7% | 12% | 11% | 10% | 11% | 4.5% |
| Other Income | 11 | 2 | 13 | −246 | −20 | 34 | 22 | 14 | 24 | 72 | 53 | 328 |
| Interest | 77 | 40 | 19 | 16 | 7 | 3 | 29 | 52 | 57 | 60 | 63 | 39 |
| Depreciation | 26 | 39 | 36 | 36 | 35 | 34 | 34 | 33 | 32 | 29 | 27 | 24 |
| PBT | −124 | −147 | −200 | −363 | −53 | 8 | −17 | −29 | −20 | 26 | 16 | 288 |
| Tax % | −7% | −2% | 0% | 0% | 1% | 0% | 15% | 1% | 2% | 0% | 14% | 2% |
| Net Profit | −116 | −145 | −200 | −364 | −54 | 8 | −19 | −30 | −20 | 26 | 14 | 283 |
| EPS (₹) | −22.97 | −28.85 | −39.75 | −67.21 | −9.99 | 1.51 | −3.53 | −5.5 | −3.69 | 4.8 | 2.63 | 52.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 84 | −64 | −264 | −636 | −690 | −688 | −724 | −706 | −731 | −716 | −702 | −413 |
| Borrowings | 1,024 | 1,054 | 1,061 | 1,062 | 1,055 | 1,010 | 1,017 | 1,023 | 1,036 | 993 | 1,014 | 874 |
| Other Liabilities | 272 | 228 | 254 | 232 | 237 | 265 | 298 | 344 | 316 | 361 | 331 | 257 |
| Total Liabilities | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
| Fixed Assets | 440 | 404 | 374 | 342 | 311 | 291 | 270 | 244 | 236 | 216 | 184 | 243 |
| CWIP | 4 | 4 | 4 | 2 | 0 | 0 | 0 | 13 | 9 | 30 | 51 | 0 |
| Investments | 45 | 45 | 45 | 44 | 44 | 41 | 24 | 70 | 64 | 54 | 1 | 6 |
| Other Assets | 900 | 775 | 638 | 281 | 258 | 267 | 308 | 344 | 323 | 349 | 418 | 480 |
| Total Assets | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
Cash Flow
₹ Cr| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 103 | 86 | −106 | 7 | 1 | 43 | 35 | 83 | 50 | 73 | 15 | 16 |
| Investing | −14 | −6 | −4 | −4 | −3 | −14 | −11 | −17 | −18 | −29 | 77 | 3 |
| Financing | −89 | −81 | 110 | −11 | −4 | −13 | −26 | −54 | −45 | −47 | −42 | −13 |
| Net Cash Flow | 0 | −1 | 0 | −8 | −5 | 16 | −3 | 12 | −13 | −3 | 50 | 6 |
| Free Cash Flow | 88 | 80 | −110 | 2 | −5 | 29 | 22 | 63 | 31 | 42 | −13 | −25 |
| CFO/EBITDA | −320 | −122 | 67 | −10 | 17 | 397 | 148 | 202 | 111 | 174 | 28 | 69 |
Ratios
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 282 | 425 | 451 | 151 | 113 | 95 | 104 | 111 | 83 | 93 | 111 | 112 |
| Inventory Days | 202 | 117 | 151 | 86 | 108 | 112 | 102 | 123 | 120 | 150 | 83 | 150 |
| Days Payable | 152 | 155 | 290 | 356 | 426 | 454 | 440 | 454 | 353 | 393 | 262 | 143 |
| Cash Conversion Cycle | 331 | 387 | 311 | −119 | −206 | −246 | −234 | −220 | −149 | −150 | −68 | 120 |
| Working Capital Days | 94 | 2 | −32 | −570 | −563 | −558 | −490 | −482 | −451 | −601 | −30 | 35 |
| ROCE % | −4% | −10% | −20% | −14% | −4% | −4% | 2% | 8% | 11% | 8% | 13% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ind-Swift insights
65 extracted metrics across FY08–FY25.
Documents
Frequently Asked Questions about Ind-Swift
What does Ind-Swift Ltd do?
Where is Ind-Swift Ltd (INDSWFTLTD) listed?
Which sector does Ind-Swift Ltd belong to?
Company Information
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDSWFTLTD.md for Ind-Swift Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.